Fiduciary Financial Group LLC Invests $315,000 in Option Care Health, Inc. $OPCH

Key Points

• Fiduciary Financial Group LLC invested $315,000 in Option Care Health, acquiring 9,848 shares during the second quarter.
• Insider transactions saw Director Norman L. Wright purchasing 3,411 shares, increasing his ownership by 28.21%, and Timothy P. Sullivan buying 20,000 shares, boosting his stake by 68.43%.
• Analysts have set a consensus price target of $35.75 for Option Care Health, with eight analysts recommending a Buy rating on the stock.

Fiduciary Financial Group LLC acquired a new stake in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 9,848 shares of the company's stock, valued at approximately $315,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. raised its stake in shares of Option Care Health by 1,492.9% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 892 shares of the company's stock valued at $31,000 after acquiring an additional 836 shares during the last quarter. Brooklyn Investment Group increased its holdings in Option Care Health by 186.6% in the first quarter. Brooklyn Investment Group now owns 1,198 shares of the company's stock valued at $42,000 after purchasing an additional 780 shares during the period. Public Employees Retirement System of Ohio raised its position in Option Care Health by 21.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock worth $43,000 after purchasing an additional 332 shares during the last quarter. Bessemer Group Inc. lifted its holdings in Option Care Health by 62.3% during the 1st quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock worth $54,000 after buying an additional 599 shares during the period. Finally, Wealthquest Corp bought a new stake in shares of Option Care Health in the 1st quarter valued at about $66,000. 98.05% of the stock is owned by institutional investors.

Insider Transactions at Option Care Health

In related news, Director Norman L. Wright bought 3,411 shares of the company's stock in a transaction on Tuesday, September 9th. The shares were purchased at an average cost of $29.31 per share, for a total transaction of $99,976.41. Following the completion of the purchase, the director directly owned 15,501 shares in the company, valued at $454,334.31. The trade was a 28.21% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Timothy P. Sullivan purchased 20,000 shares of the firm's stock in a transaction dated Thursday, August 21st. The shares were bought at an average price of $27.51 per share, with a total value of $550,200.00. Following the purchase, the director owned 49,229 shares in the company, valued at $1,354,289.79. The trade was a 68.43% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 59,411 shares of company stock worth $1,627,576 in the last ninety days. Company insiders own 0.64% of the company's stock.

Option Care Health Price Performance

Shares of OPCH opened at $28.48 on Friday. The business's fifty day moving average is $29.09 and its 200 day moving average is $31.43. Option Care Health, Inc. has a 12-month low of $21.39 and a 12-month high of $35.53. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.81. The stock has a market cap of $4.62 billion, a P/E ratio of 22.78, a P/E/G ratio of 1.79 and a beta of 0.82.

Option Care Health (NASDAQ:OPCH - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.41 EPS for the quarter, topping analysts' consensus estimates of $0.40 by $0.01. The firm had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.35 billion. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.The company's revenue for the quarter was up 15.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.30 EPS. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. Sell-side analysts anticipate that Option Care Health, Inc. will post 1.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

OPCH has been the subject of a number of analyst reports. JMP Securities raised their price objective on Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a research report on Thursday, July 31st. Barrington Research restated an "outperform" rating and set a $38.00 price target on shares of Option Care Health in a report on Thursday, July 10th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Option Care Health in a research note on Thursday, July 31st. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, Option Care Health currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.75.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.